Precaution, cyclooxygenase inhibition, and cardiovascular risk

Trends in Pharmacological Sciences

Volumn 30, Issue 10, 2009, Pages 503-508

  Ritter, James M ^a   Harding, Idris ^b   Warren, John B ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c Top Flat   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; PARACETAMOL; PARECOXIB; PLACEBO; ROFECOXIB; THROMBOXANE; VALDECOXIB;

ADENOMATOUS POLYP; ARTICLE; ATHEROMA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; LOW DRUG DOSE; PATIENT SAFETY; PRESCRIPTION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS INHIBITION; RISK BENEFIT ANALYSIS; SIDE EFFECT; SODIUM RETENTION; STOMACH DISEASE;

ANIMALS; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE INHIBITORS; DRUG LABELING; HUMANS; RISK;

EID: 70349176236     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2009.07.007     Document Type: Article

References (66)

1. Egan K.M., et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111 (2005) 334-342
2. Kobayashi T., et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J. Clin. Invest. 114 (2004) 784-794
3. FitzGerald G.A., et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N. Engl. J. Med. 310 (1984) 1065-1068
4. Patrono C., et al. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 353 (2005) 2373-2383
5. Egan K.M., et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306 (2004) 1954-1957
6. Reilly I.A., and FitzGerald G.A. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet-inhibitory drugs. Blood 69 (1987) 180-186
7. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet treatment. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
8. McAdam B.F., et al. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 272-277
9. Flavahan N.A. Balancing prostanoid activity in the human vascular system. Trends Pharmacol. Sci. 28 (2007) 106-110
10. 2. Science 296 (2002) 539-554
11. Bombardier C., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343 (2000) 1520-1528
12. Drazen J.M. COX-2 inhibitors - a lesson in unexpected problems. N. Engl. J. Med. 352 (2005) 1131-1132
13. Asif J. General Product Safety Law. In: Feldschreiber P. (Ed). The Law and Regulation of Medicines (2008), Oxford University Press 129-164
14. Kearney P.M., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 332 (2006) 1302-1308
15. McGettigan P., and Henry D. Cardiovascular risk and inhibition of cyclo-oxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclo-oxygenase 2. JAMA 296 (2006) 1633-1644
16. Curfman G.D., et al. Expression of concern. N. Engl. J. Med. 353 (2005) 2813-2814
17. Bresalier R.S., et al. The Adenomatous Polyp Prevention on Vioxx (APPROVe). Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. N. Engl. J. Med. 352 (2005) 1092-1102
18. Nissen S.E. Adverse effects of rofecoxib. N. Engl. J. Med. 355 (2006) 203-204
19. Furberg C. Adverse effects of rofecoxib. N. Engl. J. Med. 355 (2006) 204
20. Graham D.J., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective anti-inflammatory drugs: nested case control study. Lancet 365 (2005) 475-481
21. Moore, N. (2009) No obvious extra cardiovascular risk associated with low-dose NSAIDs. Clin. Pharm. Therap. (in press)
22. Garcia Rodriguez L.A., et al. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J. Am. Coll. Cardiol. 52 (2008) 1628-1636
23. Patrono C., and Rocca B. Nonsteroidal antiinflammatory drugs: past, present and future. Pharmacological Research 59 (2009) 285-289
24. Warren J.B. The Regulatory Process: pharmacovigilance in practice. In: Feldschreiber P. (Ed). The law and Regulation of Medicines (2008), Oxford University Press, Oxford 129-164
25. Topol E.J. Failing the public health: rofecoxib, Merck, and the FDA. N. Engl. J. Med. 351 (2004) 1707-1709
26. Suntharalingam G., et al. Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N. Engl. J. Med. 355 (2006) 1018-1028
27. Reddy L.R., and Corey E.J. Facile air oxidation of the conjugate base of rofecoxib (Vioxx), a possible contributor to human toxicity. Tetrahedron Lett. 46 (2005) 927-929
28. Minuz P. Nonsteroidal anti-inflammatory drugs and cardiovascular risk: is prostacyclin inhibition the key event?. J. Am. Coll. Cardiol. 52 (2008) 1637-1639
29. Patrignani P., et al. Biochemical and pharmacological characterization of the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271 (1994) 1705-1712
30. Hinz B., and Burne K. Can drug removals involving cyclooxygenase-2 inhibitors be avoided? A plea for human pharmacology. Trends Pharmacol. Sci. 29 (2008) 391-397
31. Patrono C., et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb. Res. 17 (1980) 317-327
32. Brideau C., et al. A human whole blood assay for clinical evaluation of biochemical efficacy of cyclo-oxygenase inhibitors. Inflamm. Res. 45 (1996) 68-74
33. FitzGerald G.A., et al. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67 (1983) 1174-1177
34. Patrignani P., et al. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. Clin. Invest. 69 (1982) 1366-1372
35. Clarke R.J., et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N. Engl. J. Med. 325 (1991) 1137-1141
36. Rasmanis G., et al. Effects of intermittent treatment with aspirin on thromboxane and prostacyclin formation in patients with acute myocardial infarction. Lancet 2 (1988) 245-247
37. Catella-Lawson F., et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J. Pharmacol. Exp. Ther. 289 (1999) 735-741
38. Van Hecken A., et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J. Clin. Pharmacol. 40 (2000) 1109-1120
39. FitzGerald G.A. Cox-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2 (2003) 879-890
40. McAdam B.F., and Byrne D. Contribution of cyclooxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin. Circulation 112 (2005) 1024-1029
41. Schwartz J.I., et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J. Clin. Pharmacol. 48 (2008) 745-754
42. Tacconelli S., et al. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr. Med. Res. Opin. 18 (2002) 503-511
43. Leese P.T., et al. The COX-2 selective inhibitor, valdecoxib, does not impair platelet function in the elderly: results of a randomized controlled trial. J. Clin. Pharmacol. 43 (2003) 504-513
44. Graff J., et al. Effects of parecoxib and dipyrone on platelet aggregation in patients undergoing meniscectomy: A double-blind, randomized, parallel-group study. Clinical Therapeutics 29 (2007) 438-447
45. Dallob A., et al. Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J. Clin. Pharmacol. 43 (2003) 573-585
46. Atherton C.T., et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase2 selective inhibitor an integrated study. Clin. Gastroenterol. Hepatol. 4 (2004) 113-120
47. Scott, G. et al. (2003) Multiple dose lumiracoxib shows rapid absorption and COX-2 selectivity without accumulation in patients with rheumatoid arthritis. In Tulunay FC, Orme M, eds. European collaboration towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics. Berlin: Springer, 124, p197
48. Vesterqvist O., and Gréen K. Effects of naproxen on the in vivo synthesis of thromboxane and prostacyclin in man. Eu. J. Clin. Pharmacol. 37 (1989) 563-565
49. Hinz B., et al. Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?. Annals of the Rheumatic Diseases 68 (2009) 289-291
50. Kirchheiner J., et al. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans. Br. J. Clin. Pharmacol. 55 (2003) 51-61
51. Tegeder I., et al. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin. Pharmacol. Ther. 65 (1999) 533-544
52. Nussmeier N.A., et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352 (2005) 1081-1091
53. Chen Y.F., et al. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess. 11 (2008) 1-278
54. Solomon S.D., et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117 (2008) 2104-2113
55. Patrono C., and Baigent C. Low-Dose Aspirin, Coxibs, and other NSAIDS: A Clinical Mosaic Emerges. Mol. Interv. 9 (2009) 31-39
56. Baigent C., and Patrono C. Selective COX-2 inhibitors: where do we go from here?. Lancet 372 (2008) 1712-1713
57. Chan A.T., et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 113 (2006) 1578-1587
58. Fosbøl E.L., et al. Risk of Myocardial Infarction and Death Associated With the Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Among Healthy Individuals: A Nationwide Cohort Study. Clin Pharmaco & Ther 85 (2009) 190-197
59. Gislason G.H., et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch. Intern. Med. 169 (2009) 141-149
60. Aronoff D.M., et al. New insights into the mechanism of action of acetaminophen: Its clinical pharmacologic characteristics reflect its inhibition of the two prostaglandin H2 synthases. Clin. Pharmacol. Ther. 79 (2006) 9
61. Hinz B., et al. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 22 (2008) 383-390
62. Li S., et al. Acetominophen: antipyretic or hypothermic in mice? In either case, PGHS-1b (COX-3) is irrelevant. Prostaglan Other Lipid Mediat. 85 (2008) 89-99
63. Boutard O., et al. Determinants of of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2) synthases. Proc. Nat. Acad. Sci. U.S.A 99 (2002) 7130-7135
64. Green K., et al. Pronounced reduction of in vivo prostacyclin synthesis in humans by acetaminophen (paracetamol). Prostaglandins 37 (1989) 311-315
65. Drvota V., et al. Effects of non-steroidal anti-inflammatory drugs on the in vivo synthesis of thromboxane and prostacyclin in humans. Adv. Prostaglandin Thromboxane Leukot. Res. 21A (1991) 153-156
66. Dubach U.C., et al. An epidemiologic study of abuse of analgesic drugs: effects of phenacetin and salicylate on mortality and cardiovascular morbidity (1968 to 1987). N. Engl. J. Med. 324 (1991) 155-160